Sentences with phrase «antigen receptor»

Called CAR - T cell immunotherapy (for chimeric antigen receptor T cell), one is for kids and young adults with B cell acute lymphoblastic leukemia, or ALL, approved in August (SN Online: 8/30/17).

More specifically, tisagenlecleucel is a type of chimeric antigen receptor T cell (CAR - T) therapy, a technique pioneered by immunologist Carl June and colleagues at the University of Pennsylvania.

Mutations in T - cell antigen receptor genes α and β block thymocyte development at different stages.

These assays amplify the DNA between primers that target the conserved V regions and the conserved J regions of antigen receptor genes.

The clinical hold pushes back Juno's earlier plans to pursue FDA approval next year for JCAR015, a CD19 - directed chimeric antigen receptor technology (CAR - T) product candidate that has been under study in ROCKET in adult patients with relapsed or refractory B - cell acute lymphoblastic leukemia.

Selective development of CD4 + T cells in transgenic mice expressing a class II MHC - restricted antigen receptor.

In December 2016, the New England Journal of Medicine published a study demonstrating that a chimeric antigen receptor therapy (CAR - T) caused glioblastoma regression.

These cells also shared stretches of genetic sequence that code for the same antigen receptors.

A team of virologists, geneticists, and immunologists took a close look at the Duffy antigen receptor for chemokines, more commonly known by its acronym, DARC.

The scientists took the genes for the most effective liver cancer antigen receptors on those T cells, put those receptors on human T cells and the resulting engineered human T cells eradicated the cancer as well, without hurting normal liver cells, they report in the journal Hepatology.

Kite Pharma, one of the companies chasing a new generation of cancer drugs called chimeric antigen receptor T - cell (CAR - T) therapies, announced a patient death in a clinical trial of its experimental KTE - C19.

Tests that detect TRB clonal rearrangements are useful in the study of T - cell malignancies as leukemias and lymphomas generally share one or more cell - specific or «clonal» antigen receptor gene rearrangement (s).

In mice whose brainstems were implanted with human DIPG, engineered immune cells known as chimeric antigen receptor T cells — or CAR - T cells — were able to eliminate tumors, leaving very few residual cancer cells.

D'Oro, U., Vacchio, M.S., Weissman, A.M. & Ashwell, J.D. Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation.

What makes the treatment so fascinating is its underlying technology, called chimeric antigen receptor T - cell (CAR - T).

The deal will give Gilead access to KTE - C19, which is a chimeric antigen receptor T - cell (CAR - T) therapy.

Those two companies, along with their larger competitor Novartis (nvs), are developing experimental chimeric antigen receptor T - cell (CAR - T) technology platforms, which are highly personalized treatments that involve extracting patients» immune cells, re-engineering them to target their specific cancers, and then pumping these sniper - cells back into the body.

Bellicum is among the flurry of biotechs investing heavily into cell therapies such as experimental chimeric antigen receptor T - cell (CAR - T) treatments for cancer (this is the next - gen treatment that involves reprogramming immune cells to become cancer killers and has shown promise in blood cancers, which Bellicum specializes in).

Yescarta is a so - called chimeric antigen receptor T - cell (CAR - T) treatment.

The drug, called Kymriah, is a highly personalized cancer treatment called CAR T - cell therapy (CAR is short for chimeric antigen receptor).

The race to become the first company with a chimeric antigen receptor T - cell (CAR - T) cancer therapy on the market has entered its final leg, and Kite Pharma now appears to have a big advantage.

Juno Therapeutics has halted development of JCAR015, its lead chimeric antigen receptor (CAR) T - cell cancer immunotherapy indicated for adults with relapsed / refractory B - cell acute lymphoblastic leukemia (ALL), nearly 4 months after placing a Phase II trial of the candidate on its second clinical hold following two additional patient deaths.

US - based pharmaceutical company Gilead Sciences entered the chimeric antigen receptor (CAR) T - cell therapy business through its acquisition of Kite Pharma, and Australian biopharma company CSL Behring acquired US - based Calimmune, a company that develops clinical - stage gene therapy solutions.

Santa Monica, California - based Kite is developing chimeric antigen receptor T - cell therapy, known as a CAR T, which harnesses the body's own immune cells to recognize and attack malignant cells.

At this time, trials and plans for its other CD19 - directed chimeric antigen receptor (CAR) T - cell product candidates, including JCAR017, are not affected.

Kite Pharma today reported positive 6 - month data from its pivotal ZUMA - 1 trial for its lead chimeric antigen receptor (CAR) T - cell candidate axicabtagene ciloleucel (formerly KTE - C19) in patients with chemorefractory aggressive B - cell non-Hodgkin lymphoma (NHL).

While that might not sound like a big deal, investors probably liked what Ji would be discussing: Sorrento's chimeric antigen receptor T cell (CAR - T) technology.

No. 4: CAR - T takes a backseat Research into chimeric antigen receptor T - cell (CAR - T) therapy has captured the attention of investors over the past two years, but safety risks could emerge as trial sizes increase, and that could help shift attention to other promising anti-cancer approaches, including NantKwest's (NASDAQ: NK) natural killer cell approach and soon - to - IPO Editas» CRISPR / Cas approach.

The hack that gives CAR T cells their cancer - killing abilities relies on a specially designed surface molecule called a chimeric antigen receptor (CAR)-- and hence the technique's name — which scientists incorporate into T cell genomes using a modified virus.

Summer and fall brought approval of chimeric antigen receptor (CAR) T - cell therapies for forms of leukemia and lymphoma.

A transformative cancer therapy based on modified immune cells has lured doctors, companies, and patients alike, but many are hitting a frustrating roadblock: generating enough of these chimeric antigen receptor (CAR)- T cells to meet surging demand.

Chimeric antigen receptor (CAR) T cells CAR comprising a podoplanin (PDPN)- specific antibody fragment with CD28, 4 - 1BB, and CD3?

We designed chimeric antigen receptor (CAR) T cells that specifically target podoplanin (PDPN), a key protein for the progression of solid tumors, including GBM.»

«We have successfully engineered T cells that produce special receptors on their surface, called chimeric antigen receptors (CARs), which allow the T cells to recognize specific proteins (antigens) expressed in GBM.

Those proteins, called chimeric antigen receptors, recognize the cancer cells in the patient's body.

Fifteen years ago, Campana helped develop the chimeric antigen receptor that's used in Kymriah today.

T cells genetically engineered to make the chimeric antigen receptor can recognize and target tumor cells.

Checkpoint inhibitors for various solid tumors cost about $ 150,000 a year, and a personalized treatment called chimeric antigen receptor — T cell therapy tops out at $ 475,000.

The engineered cells contain an antibody - like protein known as a chimeric antigen receptor (CAR), which is designed to bind to a protein called CD19 found on the surface of cancerous B cells.

Chimeric antigen receptor (CAR) T - cell therapies utilize a patient's own T cells that have been genetically engineered to bind to a specific antigen on target cancer cells.

The CARs that drive these treatments are custom - designed proteins called chimeric antigen receptors.